At the news
? NEUTRALIMPACT 3/10 144 filed Apr 17, 2026 at 16:34 ET
James Mule, a director at CG Oncology, filed a Form 144 to notify intent to sell up to 17,564 shares of common stock, received through the exercise of stock options. The filing indicates planned sales under a 10b5-1 plan, with option exercises occurring as early as March 2026.
- James Mule, director of CG Oncology, intends to sell 17,564 shares of common stock
- Shares were or will be acquired through exercise of stock options between March 2026 and June 2025
- Sales are being conducted under a 10b5-1 plan, indicating prearranged trading strategy
- Total value of shares to be sold is approximately $116,514 based on current market price
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access